How will the COVID pandemic end?

In an extraordinary 20 months, science has tackled the SARS-CoV-2 virus and made vaccines for adults and children. Scientists have developed monoclonal antibodies that help if given early; we now have the first drugs that could stop infections or tilt the immunological fight in favor of the patient. The number of COVID cases is going down, although in some areas like the mountain West the disease is still raging. The virus is an opportunist. Remember the 750,000 people in the United States and the millions around the world who have died.

People go without vaccines for various reasons that we know by now. People who refuse vaccines may not understand that “Fortune favors the prepared immune system,” to paraphrase Louis Pasteur’s “Fortune favors the prepared mind.” A 50-microgram injection induces antibodies that neutralize the SARS-CoV-2 coronavirus or T-cells that kill the human cells, which contain multiplying virus.  As the vaccines’ protection wanes over six months, a few elderly people in their 80s or older have died of COVID infections. The late waning can be corrected by boosters, or at least I hope so.

The grizzly experiment to test the SARS-CoV-2 vaccines has been done in Texas, Florida, Louisiana and other places where the level of vaccination is low. The virus, or more recently the delta variant, raced through the population, filling wards with COVID patients. A year-and-a-half after this disaster hit New York hospitals, other hospitals in the West and South, Alaska and other places are converting space to treating COVID-19 patients. More than 90% of their patients in intensive care were not vaccinated. Anti-vaxxers do not usually plan clinical trials, but in this case, inadvertently, they did. The vaccine protects people.

Predicting the end of the pandemic is a tricky business. We thought we had seen the end in June and July. Then, with the delta variants, the trend reversed among unvaccinated people and cases went up. Could there be more variants? Yes, but so far, the vaccines have worked against all variants. Antibodies and T-cells react with all parts of a virus protein, not just the sections that have changed in the variants.

What does medicine have to throw into this battle?  Monoclonal antibodies are being used and they work if applied early in the disease. These antibodies are produced in fermenters and must be infused intravenously. They are expensive and tricky to use. Fighting an epidemic, especially in poor areas of the world and of the United States, demands simplicity.

There is a drug, malnupiravir, that if given early in an infection often controls it. It was developed at Emory University in Atlanta and licensed to Merck for production. Malnupiravir is a cleverly designed molecule that gets incorporated into new viruses and mutates them out of existence.  It has been approved for use in the United Kingdom. It may block infection in people who have been exposed to the virus. That will be known soon. Merck will not enforce patent restrictions.

Pfizer also has a promising drug that works by a mechanism that is different from that of malnupiravir. The difference is important because viruses often mutate to become resistant to one oral drug. In the case of HIV, several drugs were required to stop infection. Pfizer’s drug is also well along in phase 3 clinical trials and may soon receive an Emergency Use Authorization.

Excited journalists are writing about these drugs as game changers, but that is premature. A drug or combinations of drugs must have changed the game to be called a game changer. On a population basis, that remains to be seen. I am hopeful, but a little caution is in order. On a more hopeful note, drugs like these have worked for HIV, Hepatis C virus, and Dengue virus. Producing and distributing these drugs for the whole world will take time.

My prediction is that COVID-19 will recede in areas of high vaccination. All treatments will have a role, but vaccination will play the primary one. In areas where vaccination rates are low, say 40%, there will be serious problems with high levels of infection and overwhelmed medical facilities for extended periods. That patient load affects a hospital’s ability to treat other diseases. The poor and medically underserved will get even less attention. Schools, industry, and the economy are weakened. Society becomes very cranky, even violent. The vaccines, and perhaps the drugs, offer an off ramp from this disaster.

Richard Kessin lives in Norfolk and is Emeritus Professor of Pathology and Cell Biology at the Columbia University Irving Medical Center. See other essays at RichardKessin.com or at The Lakeville Journal. www.tricornernews.com/category/opinion-author/body-scientific. E-mail: Richard.Kessin@gmail.com.

The views expressed here are not necessarily those of The Lakeville Journal and The Journal does not support or oppose candidates for public office.

Latest News

Salisbury property assessments up about 30%; Tax rate likely to drop
Salisbury Town Hall
Alec Linden

SALISBURY — Salisbury’s outside contractor, eQuality, has completed the town’s required five-year revaluation of all properties.

Proposed assessments were mailed to property owners in mid-December and show a median increase of approximately 30% to 32% across the grand list.

Keep ReadingShow less
HVA awards spotlight ‘once-in-a-generation’ land conservation effort anchored in Salisbury

Grant Bogle, center, poses with his Louis and Elaine Hecht Follow the Forest Award with Julia Rogers, left, and Tim Abbott, during HVA’s 2025 Annual Meeting and Holiday Party.

Photo by Laura Beckius / HVA

SALISBURY — From the wooded heights of Tom’s Hill, overlooking East Twin Lake, the long view across Salisbury now includes a rare certainty: the nearly 300-acre landscape will remain forever wild — a milestone that reflects years of quiet local organizing, donor support and regional collaboration.

That assurance — and the broader conservation momentum it represents — was at the heart of the Housatonic Valley Association’s (HVA) 2025 environmental awards, presented in mid-December at the organization’s annual meeting and holiday party at The Silo in New Milford.

Keep ReadingShow less
Northwest Corner voters chose continuity in the 2025 municipal election cycle
Lots of lawn signs were seen around North Canaan leading up to the Nov. 4 election.
Christian Murray

Municipal elections across Northwest Connecticut in 2025 largely left the status quo intact, returning longtime local leaders to office and producing few changes at the top of town government.

With the exception of North Canaan, where a two-vote margin decided the first selectman race, incumbents and established officials dominated across the region.

Keep ReadingShow less
The hydrilla menace: 2025 marked a turning point

A boater prepares to launch from O’Hara’s Landing at East Twin Lake this past summer, near the area where hydrilla was first discovered in 2023.

By Debra Aleksinas

SALISBURY — After three years of mounting frustration, costly emergency responses and relentless community effort, 2025 closed with the first sustained signs that hydrilla — the aggressive, non-native aquatic plant that was discovered in East Twin Lake in the summer of 2023 — has been pushed back through a coordinated treatment program.

The Twin Lakes Association (TLA) and its coalition of local, state and federal scientific partners say a shift in strategy — including earlier, whole-bay treatments in 2025 paired with carefully calibrated, sustained herbicide applications — yielded results not seen since hydrilla was first identified in the lake.

Keep ReadingShow less